Peptide Comparison
AHK-Cu vs Vialox
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
AHK-Cu and Vialox share the cosmetic class and carry roughly equivalent evidence (Cosmetic Clinical Studies / Cosmetic Clinical Studies). On the catalogued data layer Vialox has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Vialox's evidence base is currently denser.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| AHK-Cu | Vialox | |
|---|---|---|
| Class | Copper tripeptide (cosmetic) | Cosmetic peptide (Botox-like topical) |
| Drug class | Dermatologic | Dermatologic |
| Mechanism | Copper delivery to hair follicles; angiogenesis and VEGF induction in scalp | Competitive ACh receptor antagonist at neuromuscular junction |
| Route | Topical | Topical |
| Half-life | Topical (no systemic) | Topical |
| Dosage (research) | Topical 0.01-0.1% | Topical 3-5% |
| Evidence tier | Cosmetic Clinical Studies | Cosmetic Clinical Studies |
| Research depth | 3 indexed | 11 indexed |
| Availability | Cosmetic | Cosmetic |
| Reported risks | Skin irritation; theoretical copper issues | Minimal |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick AHK-Cu or Vialox?
AHK-Cu and Vialox share the cosmetic class and carry roughly equivalent evidence (Cosmetic Clinical Studies / Cosmetic Clinical Studies). On the catalogued data layer Vialox has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Vialox's evidence base is currently denser.
What is the difference between AHK-Cu and Vialox?
AHK-Cu is classed as Copper tripeptide (cosmetic); Vialox is classed as Cosmetic peptide (Botox-like topical). Reported mechanism: AHK-Cu, Copper delivery to hair follicles; angiogenesis and VEGF induction in scalp; Vialox, Competitive ACh receptor antagonist at neuromuscular junction. Reported half-life: AHK-Cu, Topical (no systemic); Vialox, Topical. Routes in published studies: AHK-Cu, Topical; Vialox, Topical.
Which has stronger evidence, AHK-Cu or Vialox?
AHK-Cu and Vialox sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. AHK-Cu is graded Cosmetic Clinical Studies, with 3 cited sources on its reference page and 3 indexed studies. Vialox is graded Cosmetic Clinical Studies, with 4 cited sources on its reference page and 11 indexed studies.
Which is more accessible, AHK-Cu or Vialox?
Neither AHK-Cu nor Vialox is an FDA-approved drug. Catalog status: AHK-Cu, Cosmetic; Vialox, Cosmetic.
Are AHK-Cu and Vialox ever combined?
AHK-Cu and Vialox appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…